drugset / Trial / NCT06364046

Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC

NCT06364046

RandomizedParallel-groupOpen-labelTreatment

Summary

This project aims to conduct a prospective, single-center, randomized, open-label, two-arm study to compare the clinical efficacy and safety of bronchial arterial chemoembolization with drug-eluting beads (DEB-BACE) combined with serplulimab versus conventional intravenous chemotherapy combined with Serplulimab as first-line treatment for SCLC patients. The objective is to provide evidence-based support for clinical practice.

Timeline

Start
2024-04-01
Primary completion
2024-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Serplulimab Monoclonal antibody 200 mg Intravenous